A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 132-139

  Akter, K ^a   Gallo, D A ^a   Martin, S A ^a   Myronyuk, N ^a   Roberts, R T ^a   Stercula, K ^a   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Clinical trials; Docosahexaenoic acid; Eicosapentaenoic acid; Essential fatty acids; Fish oil; Omega 3; Omega 6; Schizophrenia

Indexed keywords

ARACHIDONIC ACID; CLOZAPINE; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FISH OIL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LINOLEIC ACID; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

ADD ON THERAPY; BRAIN FUNCTION; CELL MEMBRANE; CLINICAL TRIAL (TOPIC); DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; HUMAN; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SYMPTOM; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ARACHIDONIC ACID; BRAIN; CELL MEMBRANE; CLINICAL TRIALS AS TOPIC; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; FISH OILS; HUMANS; NEURONS; SCHIZOPHRENIA;

EID: 84857972069     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01265.x     Document Type: Review

References (68)

1. Kidd PM Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Alternative Medicine Review, 2007;12:207-227. (Pubitemid 47613220)
2. Horrobin DF, Glen AI, Vaddadi K The membrane hypothesis of schizophrenia. Schizophrenia Research, 1994;13:195-207. (Pubitemid 24302649)
3. Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature, 1991;353:164-167. (Pubitemid 21912481)
4. Fenton WS, Hibbeln J, Knable M Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry, 2000; 47:8-21. (Pubitemid 30016075)
5. Steullet P, Neijt HC, Cuenod M, Do KQ Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience, 2006;137:807-819. (Pubitemid 43053945)
6. Berger GE, Wood SJ, Wellard RM et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology, 2008;33:2467-2473.
7. Horrobin DF The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research, 1998;30:193-208. (Pubitemid 28189552)
8. American Psychiatric Association (APA) (2000) DSM-IV-TR: Diagnostic and statistical manual of mental disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association.
9. McGrath J, Saha S, Chant D, Welham J Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews, 2008;30:67-76.
10. McDonald C, Murphy KC The new genetics of schizophrenia. Psychiatric Clinics of North America, 2003;26:41-63. (Pubitemid 36384347)
11. Seeman P Brain dopamine receptors in schizophrenia and tardive dyskinesia. Psychopharmacology Supplementum, 1985;2:1-8.
12. Meltzer HY What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology, 2004;4:53-57. (Pubitemid 38145838)
13. Muench J, Hamer AM Adverse effects of antipsychotic medications. American Family Physician, 2010;81:617-622.
14. Fahy E, Subramaniam S, Brown HA et al. A comprehensive classification system for lipids. Journal of Lipid Research, 2005;46:839-861.
15. Ratnayake WM, Galli C Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Annals of Nutrition and Metabolism, 2009;55:8-43.
16. Wainwright PE Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proceedings of the Nutrition Society, 2002;61:61-69. (Pubitemid 34171047)
17. Gorjao R, Azevedo-Martins AK, Rodrigues HG et al. Comparative effects of DHA and EPA on cell function. Pharmacology and Therapeutics, 2009;122: 56-64.
18. Singh M Essential fatty acids, DHA and human brain. Indian Journal of Pediatrics, 2005;72:239-242.
19. Fetterman JW Jr, Zdanowicz MM Therapeutic potential of n-3 polyunsaturated fatty acids in disease. American Journal of Health System Pharmacy, 2009;66:1169-1179.
20. Harris WS Fish oil supplementation: evidence for health benefits. Cleveland Clinic Journal of Medicine, 2004;71:208-210, 212, 215-208 passim.
21. Kris-Etherton PM, Harris WS, Appel LJ Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 2002;106:2747-2757. (Pubitemid 35364932)
22. Haag M Essential fatty acids and the brain. Canadian Journal of Psychiatry, 2003;48:195-203. (Pubitemid 36603376)
23. Singh M Nutrition, brain and environment: how to have smarter babies? Indian Pediatrics, 2003;40:213-220. (Pubitemid 36362626)
24. Ross BM, Katzman M Stability of methylnicotinate in aqueous solution as utilized in the 'niacin patch test'. BMC research notes, 2008;1:89.
25. Yao JK, Leonard S, Reddy RD Membrane phospholipid abnormalities in post-mortem brains from schizophrenic patients. Schizophrenia Research, 2000;42:7-17. (Pubitemid 30116755)
26. Peet M, Laugharne JD, Horrobin DF, Reynolds GP Arachidonic acid: a common link in the biology of schizophrenia? Archives of General Psychiatry, 1994;51:665-666. (Pubitemid 24249109)
27. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry, 1991;30:795-805.
28. Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biological Psychiatry, 1987;22:421-426. (Pubitemid 17041622)
29. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biological Psychiatry, 1990;28:495-501. (Pubitemid 20298440)
30. Noponen M, Sanfilipo M, Samanich K et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry, 1993;34:641-649.
31. Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Research, 1999;821:407-413. (Pubitemid 29222805)
32. Albers M, Meurer H, Marki F, Klotz J Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry, 1993;26:94-98. (Pubitemid 23166390)
33. Kovaleva ES, Orlov ON, Tsutsu'lkovskaia M, Vladimirova TV, Beliaev BS [Lipid peroxidation processes in patients with schizophrenia]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova, 1989;89:108-110.
34. Smesny S, Rosburg T, Nenadic I et al. Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage, 2007;35:729-737. (Pubitemid 46400550)
35. Smalheiser NR, Dissanayake S, Kapil A Rapid regulation of neurite outgrowth and retraction by phospholipase A2- derived arachidonic acid and its metabolites. Brain Research, 1996;721: 39-48. (Pubitemid 26179835)
36. Negre-Aminou P, Nemenoff RA, Wood MR, de la Houssaye BA, Pfenninger KH Characterization of phospholipase A2 activity enriched in the nerve growth cone. Journal of Neurochemistry, 1996;67:2599-2608. (Pubitemid 26392533)
37. Poltorak M, Frye MA, Wright R et al. Increased neural cell adhesion molecule in the CSF of patients with mood disorder. Journal of Neurochemistry, 1996;66:1532-1538. (Pubitemid 26090556)
38. Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 2010;67:146-154.
39. Irving CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. The Cochrane Database of Systematic Reviews, Issue 3.
40. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK Two double-blind placebocontrolled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 2001;49:243-251. (Pubitemid 32453225)
41. Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J Essential fatty acid supplementation in tardive dyskinesia. American Journal of Psychiatry, 1986;143:912-914. (Pubitemid 16090404)
42. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry, 2001;158:2071-2074. (Pubitemid 33104119)
43. Berger GE, Proffitt TM, McConchie M et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 2007;68:1867-1875.
44. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry, 2002;159:1596-1598. (Pubitemid 35006744)
45. Peet M, Horrobin DF A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research, 2002;36:7-18. (Pubitemid 34037843)
46. Emsley R, Niehaus DJ, Koen L et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research, 2006;84:112-120. (Pubitemid 44255716)
47. Christensen O, Christensen E Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica, 1988;78:587-591.
48. Sampath HM Prevalence of psychiatric disorders in a southern Baffin Island Eskimo settlement. Canadian Psychiatric Association Journal, 1974;19:363-367.
49. Noaghiul S, Hibbeln JR Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry, 2003;160:2222-2227. (Pubitemid 39619617)
50. Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. New England Journal of Medicine, 1989;320:265-271. (Pubitemid 19045549)
51. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. New England Journal of Medicine, 1996;334:1557-1560. (Pubitemid 26177482)
52. Kremer JM n-3 fatty acid supplements in rheumatoid arthritis. American Journal of Clinical Nutrition, 2000;71:349S-351S. (Pubitemid 30046140)
53. Wang C, Harris WS, Chung M et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. American Journal of Clinical Nutrition, 2006;84:5-17. (Pubitemid 44699166)
54. Mayer K, Schaefer MB, Seeger W Fish oil in the critically ill: from experimental to clinical data. Current Opinion in Clinical Nutrition and Metabolic Care, 2006;9:140-148. (Pubitemid 44090038)
55. Smith W, Mitchell P, Leeder SR Dietary fat and fish intake and age-related maculopathy. Archives of Ophthalmology, 2000;118:401-404. (Pubitemid 30152382)
56. Boudrault C, Bazinet RP, Ma DW Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. The Journal of Nutritional Biochemistry, 2009;20:1-10.
57. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. American Journal of Clinical Nutrition, 2007;85:1103-1111. (Pubitemid 46557928)
58. Engelhart MJ, Geerlings MI, Ruitenberg A et al. Diet and risk of dementia: does fat matter?: The Rotterdam Study. Neurology, 2002;59:1915-1921. (Pubitemid 36076564)
59. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S Fish, meat, and risk of dementia: cohort study. British Medical Journal, 2002;325:932-933. (Pubitemid 35265208)
60. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Archives of Neurology, 2006;63:1402-1408. (Pubitemid 44547551)
61. Calon F, Lim GP, Yang F et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron, 2004;43:633-645. (Pubitemid 39179724)
62. Peet M, Murphy B, Shay J, Horrobin D Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry, 1998;43:315-319. (Pubitemid 28137622)
63. Mischoulon D Update and critique of natural remedies as antidepressant treatments. Obstetrics and Gynecology Clinics of North America, 2009;36:789-807, x.
64. Kiecolt-Glaser JK, Belury MA, Porter K, Beversdorf DQ, Lemeshow S, Glaser R Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosomatic Medicine, 2007;69:217-224. (Pubitemid 46653073)
65. Peet M, Horrobin DF A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry, 2002;59:913-919.
66. Rees AM, Austin MP, Owen C, Parker G Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Research, 2009;166:254-259.
67. Simopoulos AP, Leaf A, Salem N Jr Workshop statement on the essentiality of and recommended dietary intakes for Omega- 6 and Omega-3 fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2000;63:119-121.
68. Burgess JR, Stevens L, Zhang W, Peck L Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition, 2000;71:327S-330S. (Pubitemid 30046136)